Head-To-Head Review: Sema4 (SMFR) vs. The Competition

Sema4 (NASDAQ:SMFRGet Rating) is one of 33 publicly-traded companies in the “Health services” industry, but how does it weigh in compared to its rivals? We will compare Sema4 to similar companies based on the strength of its risk, profitability, institutional ownership, valuation, analyst recommendations, earnings and dividends.


This table compares Sema4 and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sema4 -121.31% -53.31% -36.04%
Sema4 Competitors -325.87% -481.25% -38.19%

Institutional and Insider Ownership

47.2% of shares of all “Health services” companies are held by institutional investors. 22.1% of shares of all “Health services” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Sema4 and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sema4 0 1 4 0 2.80
Sema4 Competitors 7 128 274 0 2.65

Sema4 currently has a consensus target price of $3.08, suggesting a potential upside of 395.55%. As a group, “Health services” companies have a potential upside of 113.22%. Given Sema4’s stronger consensus rating and higher probable upside, equities analysts clearly believe Sema4 is more favorable than its rivals.

Earnings and Valuation

This table compares Sema4 and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Sema4 $212.20 million -$245.39 million -0.67
Sema4 Competitors $1.36 billion -$98.47 million 28.41

Sema4’s rivals have higher revenue and earnings than Sema4. Sema4 is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Sema4 has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, Sema4’s rivals have a beta of 1.48, meaning that their average stock price is 48% more volatile than the S&P 500.


Sema4 beats its rivals on 7 of the 12 factors compared.

Sema4 Company Profile

(Get Rating)

Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.

Receive News & Ratings for Sema4 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sema4 and related companies with MarketBeat.com's FREE daily email newsletter.